Moderna, Inc.
https://www.modernatx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Moderna, Inc.
US FDA Advisors Urge Faster Movement, mRNA Consideration, In Updating Pandemic Flu Vaccines
The FDA’s vaccine advisory committee endorsed a new plan to update pandemic influenza vaccines “inter-pandemic,” but encouraged the agency to consider how to make the approach feasible for novel vaccine technologies.
GSK’s Arexvy Reinforces Its Lead In A Stalling RSV Vaccine Market
Arexvy has become the first RSV vaccine to show it can provide protection over three years – but that might mean lower market uptake than originally expected.
US FDA Proposes New ‘Inter-Pandemic’ Pathway For Updating Flu Vaccines
The threat of a highly pathogenic avian influenza pandemic spurred the FDA to have its vaccine advisory committee comment on a new process to update licensed prototype pandemic flu vaccines.
Roche’s Xofluza Can Reduce Flu Transmission, Giving It Potential Market Boost
The company said the CENTERSTONE study marked the first time a global Phase III trial showed reduced transmission of influenza.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Vaccines
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
-
Drug Discovery Technologies
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- Caperna LLC
- Moderna Therapeutics, Inc.
- Moderna LLC
- Newco LS18, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice